Skip to content

Study comparing drug Levobupivacaine alone versus Levobupivacaine with buprenorphine as an adjuvant in ultrasound guided supraclavicular brachial plexus block

Comparative study of Levobupivacaine alone versus Levobupivacaine with buprenorphine as an adjuvant in ultrasound guided supraclavicular brachial plexus block - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/07/113447
Enrollment
60
Registered
2026-07-06
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: V224- Motorcycle driver injured in collision with two- or three-wheeled motor vehicle in traffic accident Health Condition 2: V234- Motorcycle driver injured in collision with car, pick-up truck or van in traffic accident Health Condition 3: V200- Motorcycle driver injured in collision with pedestrian or animal in nontraffic accident Health Condition 4: V240- Motorcycle driver injured in collision with heavy transport vehicle or bus in nontraffic accident Health Condition 5:

Interventions

Intervention1: Drug B Levobupivacaine and Buprenorphine: Drug B is Levobupivacaine plus Buprenorphine as an adjuvant in supraclavicular brachial plexus block for orthopaedic procedures forearm and han

Sponsors

Apollo Adlux Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA grade 1 to 3 ,patients scheduled for orthopaedic forearm and hand surgeries,

Exclusion criteria

Exclusion criteria: ASA grade 4 and above, patients with neuropathy , patients with history of bleeding disorders,patients with history of coagulation disorders,patients with any local site infection,patients with cognitive impairment

Design outcomes

Primary

MeasureTime frame
To compare the duration of analgesia when Drug A Levobupivacaine alone is used vs Drug B Levobupivacaine plus Buprenorphine used as an adjuvantTimepoint: We shall check for the outcome at 4 week and 8 weeks

Secondary

MeasureTime frame
secondary outcomes is that we expect to find out the onset & duration of sensory & motor blockTimepoint: Secondary outcome are also measured at 4 & 8 weeks

Countries

India

Contacts

Public ContactDr Eby Eldos

Apollo Adlux Hospital

Prashanthmenon@gmail.com9742341452

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026